Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can hepatology lead the way? Synthesising current global curricula and proposing a model for an international speciality curriculum.

Clinical medicine (London, England)·2026
Same author

Effect of tiomolibdate choline on copper balance in patients with Wilson disease: An open-label phase 2 trial.

Hepatology communications·2026
Same author

Wilson disease is a single gene disorder - comprehensive analysis of patients with prior negative genetic testing.

JHEP reports : innovation in hepatology·2026
Same author

Rethinking coeliac disease care: why psychological understanding matters.

The lancet. Gastroenterology & hepatology·2026
Same author

Evaluation of novel assays of non-ceruloplasmin copper to monitor chelation treatment in patients with Wilson disease.

JHEP reports : innovation in hepatology·2026
Same author

Challenging times in medical education in the era of artificial intelligence can provide opportunities.

Clinical medicine (London, England)·2025

Related Experiment Video

Updated: Jun 13, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Genetic testing for Wilson disease: availability and utility.

Michael L Schilsky1, Aftab Ala

  • 1Departments of Medicine and Surgery, Division of Digestive Diseases and Transplant and Immunology, Yale University School of Medicine, New Haven, CT 06520, USA. Michael.Schilsky@yale.edu

Current Gastroenterology Reports
|April 29, 2010
PubMed
Summary
This summary is machine-generated.

Genetic testing for Wilson disease (a copper metabolism disorder) significantly improves diagnosis, especially when clinical data is unclear. This allows for timely treatment to prevent copper-induced injury.

More Related Videos

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

Related Experiment Videos

Last Updated: Jun 13, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Medical Diagnostics

Background:

  • Wilson disease is a genetic disorder affecting copper metabolism.
  • It typically manifests in the second and third decades with hepatic or neuropsychiatric symptoms.
  • Accurate diagnosis is crucial as treatment is lifelong.

Purpose of the Study:

  • To highlight the advancements in diagnosing Wilson disease using genetic testing.
  • To emphasize the importance of genetic testing for accurate patient identification.
  • To discuss the role of molecular diagnostics in managing Wilson disease.

Main Methods:

  • Direct sequencing of the ATP7B gene for mutations.
  • Haplotype analysis for cases with a single identified mutation.
  • Direct testing for specific mutations in certain populations.

Main Results:

  • Genetic testing enhances diagnostic accuracy, particularly in ambiguous cases.
  • It aids in identifying affected patients and carriers, even without clear clinical or biochemical evidence.
  • Molecular diagnostics are becoming the standard for Wilson disease diagnosis.

Conclusions:

  • Molecular genetic testing, including ATP7B sequencing, is the standard for Wilson disease diagnosis.
  • Despite barriers like cost and interpretation, genetic testing will be integrated into routine diagnostics.
  • Timely diagnosis through genetic testing can lead to prevention or reversal of copper-induced injury.